Bio-Gate and OSSIS expand into additional international markets with HyProtect™ Coatings on Compassionate Care implants

• Stronger and expanded international market access of OSSIS after
  acquisition by Zimmer Biomet
• Increased awareness of HyProtect™ coatings
• Increased volume of HyProtect™ coated implants

Nuremberg/Bremen, 24 May 2023 – Bio-Gate AG (ISIN DE000BGAG981), a leading provider of innovative technologies and individual solutions for health and hygiene, will introduce and market the innovative HyProtect™ coating technology into additional markets in the future via its long-term partner OSSIS Ltd. from New Zealand. The cooperation primarily relates to single patient compassionate care cases in human medicine with orthopedic revision implants.

Bio-Gate has already been successfully working together with OSSIS for several years, coating revision implants with the HyProtect™ technology. Bio-Gate coats titanium implants that are manufactured by Ossis using 3D printing and which are predominantly used in orthopedic revisions for patients who are particularly at risk of infection. Our cooperation partner recently accepted an acquisition offer from Zimmer Biomet – a global medical device technology manufacturer. The cooperation with BioGate will continue unchanged and, due to the high quality of the HyProtect™ coating in the compassionate care sector, will now even be extended to further regions worldwide via the expanded global network.

Bio-Gate coated titanium implants have already been used in well over a hundred single-patient revision surgeries. Single-patient cases with antimicrobial implants are mainly performed in patients that are at risk of infection due to previous orthopedic revisions or in cancer patients. This is because in these patient groups, recent infections can lead to amputations or even have life-threatening consequences. Worldwide, patients in the EU, Switzerland, Great Britain, New Zealand, Australia and the USA have been treated with implants coated by BioGate. In Germany, for example, implants have already been coated for high-risk patients at the Professional University Clinic Cooperative Murnau, University Clinic Regensburg, University Clinic Giessen.

The successful single patient revision cases have led to a strong interest among international clinics and surgeons. By now, Bio-Gate has accumulated an extensive amount of data from medical devices implanted in humans and can prove the high quality of the HyProtect™ coating in practical use applications. The successful operations together with positive scientific publications have already led to hospitals explicitly requesting implants with Bio-Gate’s coating from manufacturers for highrisk patients. Thomas Konradt, Director of Business Development at Bio-Gate AG: “We are very pleased that our cooperation partner wants to take advantage of the new, worldwide marketing opportunities for our HyProtect™ coating through the expanded network.

The high quality of the HyProtect™ coating, which greatly reduces the risk of reinfection in patients who are particularly at risk of infection, will thus become even more widely known. In addition, the total number of implants manufactured using the 3D printing process is expected to increase in the future. This will increase the number of single patient compassionate care cases and is extremely helpful in developing our medical technology business into a growth driver.”

About Bio-Gate AG

The medical technology company Bio-Gate AG develops and markets applications which use unique silver technology to help prevent infections and thus to improve health. Bio-Gate AG’s specialty is using pure silver to treat materials and surfaces that are used in all areas of daily life – thus providing long-term and medically effective protection against bacteria, microorganisms and other pathogens. Bio-Gate AG works in three fields to supply a variety of products that provide antimicrobial protection: material enhancement, surface coating and testing the antimicrobial or anti-adhesive properties of materials. The Nuremberg-based company offers systems that stretch across the entire value-adding chain, from development to approval to production. For more information, please visit www.bio-gate.de.

Disclaimer: This publication constitutes neither an offer to sell nor an invitation to buy securities. The shares in BioGate AG (the “Shares”) may not be offered or sold in the United States or to or for the account or benefit of “U.S. persons” (as such term is defined in Regulation S under the U.S. Securities Act of 1933, as amended (the “Securities Act”)). The securities have already been sold.